Why market access hiring is getting harder to separate from evidence strategy
Market access talent is no longer defined only by account relationships or pricing support. In the US, access decisions sit inside a reimbursement system that spans Medicare, Medicaid, private insurance and Marketplace coverage, all at significant scale. CMS reported national health expenditures of $5.3 trillion in 2024, equal to $15,474 per person and 18.0% of GDP. Within that total, private health insurance accounted for $1,644.6 billion, Medicare for $1,118.0 billion and Medicaid for $931.7 billion. For employers, that scale matters because each channel brings different coverage rules, evidence expectations and budget pressures.
That is why health economics recruitment has become a strategic hiring issue rather than a narrow technical search. Organizations need people who can read policy changes, understand payer incentives and translate evidence into coverage and access choices. The public data do not provide a government count of market access jobs, but they do show the size and complexity of the financing environment those professionals must navigate.
Drug-spending pressure is raising the value of reimbursement and pricing fluency
Prescription drugs remain a focal point for market access teams. CMS said retail prescription-drug spending reached $467.0 billion in 2024, up 7.9%, after growing 10.8% in 2023. CMS also projects average annual retail prescription-drug spending growth of 5.7% for 2025 through 2034. In a growth environment like that, employers need talent that can connect clinical value, utilization assumptions, formulary positioning and gross-to-net considerations.
The practical implication is that market access roles increasingly reward candidates who can move between commercial and public payer questions with confidence. That includes reimbursement analytics, launch sequencing, contracting support and evidence translation for budget-sensitive decision makers. The case for these skills comes from the spending and growth picture itself, not from any federal workforce tally.
Medicare negotiation has made policy literacy a frontline capability
CMS selected 10 drugs for the first Medicare Drug Price Negotiation cycle, with Maximum Fair Prices taking effect on January 1, 2026. CMS said those products were dispensed to about 8.8 million Medicare Part D enrollees and represented $56.2 billion, or roughly 20%, of Part D gross covered drug costs in 2023. CMS further estimated that if the negotiated prices had applied to 2023 utilization, aggregate net spending would have been 22% lower, generating about $6 billion in Medicare net savings.
For hiring managers, the lesson is not simply that negotiation exists, but that access teams now need people who can operationalize it. Strong candidates increasingly need fluency in Medicare benefit design, statutory and policy interpretation, scenario modeling, payer communication and cross-functional execution. These are role implications drawn from the policy shift and its financial scale; CMS is not publishing a direct measure of labor demand for these functions.
Real-world evidence and HEOR are moving closer to access decisions
Evidence requirements are also broadening. FDA's Advancing Real-World Evidence program runs across fiscal years 2023 through 2027, with submissions accepted through March 31, 2027. That matters for market access hiring because organizations need professionals who understand how observational data, claims, electronic health records and study design can support decision-making across development and commercialization.
In practice, this strengthens demand for hybrid profiles: people who can bridge HEOR, outcomes research, comparative evidence and reimbursement strategy. The value is not limited to regulatory interaction. The same evidence disciplines help market access teams build payer narratives, test assumptions and prepare for more skeptical reviews of value, utilization and patient impact.
Coverage growth means more stakeholders, not fewer
The US coverage base remains large across public and private programs, which increases the number of decision points market access teams must account for. CMS reported 24,166,491 Marketplace plan selections for 2025. CMS Fast Facts also reported average enrollment of 34.0 million in Original Medicare, 35.3 million in Medicare Advantage and other health plans, and 78.8 million in Medicaid and CHIP, while noting the figures are preliminary.
That breadth reinforces a simple hiring reality: market access talent has to work across multiple evidence audiences at once. Employers benefit from candidates who can tailor value messages for government programs, managed care organizations, provider systems and internal commercial teams without losing analytical rigor. In many searches, the strongest hires are those who can connect policy change, evidence generation and field execution instead of treating them as separate disciplines.
For US employers, market access talent is becoming harder to hire because the job itself is changing. The strongest candidates increasingly combine reimbursement knowledge with HEOR, real-world evidence, policy interpretation and implementation discipline. For Sunrise Consultant Company, that makes market access hiring less about filling a title and more about finding professionals who can turn evidence-heavy complexity into workable access decisions.
Sources
- NHE Fact Sheet - CMS 2026-06-24
- [PDF] National Health Expenditures 2024 Highlights - CMS 2026-08-26
- [PDF] Medicare Drug Price Negotiation Program - CMS 2026-08-19
- National Health Expenditure Data - CMS 2025-09-22